NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENO-DIP (diatrizoate meglumine) is a high-osmolarity contrast medium administered by injection for radiographic imaging procedures. It enhances visualization of internal body structures during X-ray and fluoroscopy examinations. The drug works through osmotic effects that increase radiodensity in target anatomical regions.
LOE Approaching
LOE-stage product with moderate competitive pressure (30/100) suggests consolidation and efficiency-focused teams rather than growth-phase hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENO-DIP offers limited career growth potential given its LOE-approaching status and zero linked job openings. Roles on this product prioritize cost management, market defense, and operational efficiency over innovation and expansion. Career advancement would depend on transition to growth-stage products within Bracco's portfolio.
Brand ManagerProduct Manager
Worked on RENO-DIP at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.